The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials
Pooled result · Body weightResult — go to the resultWMD −0.97 kg 95 % CI −1.10 to −0.83Authors' conclusion
Lixisenatide was found to significantly decrease BW and BMI in patients with type 2 DM and could be considered as a therapeutic option for those suffering from weight gain caused by other anti-diabetic agents. However, while prescribing Lixisenatide, careful consideration of patient-specific factors is recommended.
Study context
- Population
- Patients with T2D; Randomized controlled trials (RCTs) from four databases, inception to February 202323 articles · 26 RCT arms
- Comparison
- Subcutaneous lixisenatide vs control
- Outcome
- Body weight and BMI
Methodological detailsrandom-effects model, meta-regression
- Random-effects model
- Meta-regression
Pooled result
Body weight
Weighted mean differences (WMD)
−0.97 kg
95 % CI −1.10 to −0.83
P < 0.001
Lixisenatidevs Control
WMD −0.97 kg (95 % CI −1.10 to −0.83); P < 0.001
As reported in the abstract
Further pooled results
| Outcome | WMD (kg/m²) (95 % CI) | P value | |
|---|---|---|---|
| BMI | −0.48 (−0.67 to −0.29) | P < 0.001 | |
| −1−0.500.5Difference, kg/m² (linear scale) |
| Outcome | WMD (kg) (95 % CI) | P value | |
|---|---|---|---|
| Body weight, subgroup: RCTs lasting <24 weeks | −1.56 (−2.91 to −0.20) | P < 0.001 | |
| Body weight, subgroup: daily dose <19 µg/day | −1.94 (−2.54 to −1.34) | P < 0.001 | |
| Body weight, subgroup: mean age ≥60 years | −1.86 (−3.16 to −0.57) | P = 0.005 | |
| −4−202Difference, kg (linear scale) |
Original publication
The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials. Diabetes Res Clin Pract. Published 14 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →